Dengue is a mosquito-borne viral infection, most commonly by the yellow fever (Aedes aegypti) mosquito.
The infection causes flu-like illness, and occasionally develops into a potentially lethal complication called severe dengue.
The global incidence of dengue has grown dramatically in recent decades. About half of the world’s population is now at risk.
Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.
Severe dengue is a leading cause of serious illness and death among children in some Asian and Latin American countries.
There is no specific treatment for dengue/ severe dengue, but early detection and access to proper medical care lowers fatality rates below 1%.
Countries or areas at risks of Dengue transmission (World Health Organisation, 2013)
The contour lines of the January and July isotherms indicate areas at risk, defined by the gerographical limits of the north and southern hemispheres for year round survival of the yellow fever mosquito.
The Cause and Effect of Dengue Fever
Four serotypes of dengue virus exist in the endemic areas of the world. Primary infection results in mild symptoms and confers immunity to subsequent infection by the same serotype. Secondary infections are more severe leading to Dengue hemorrhagic fever.
Dengue is a member of the Flavi virus family
Four serotypes exist (DENV 1, 2, 3, 4)
The virus is tramised by the tiger mosquito (Aedes spp.)
1st Infection
DENV serotype
Any of the 4 DENV serotypes
Diseases
Symptoms: Mild (Dengue Fever similar to other infections such as flu or malaria)
Confers immunity against 1 DENV serotype
2nd infection
DENV serotype
DENV serotype different from 1st infection
Diseases
Symptoms: Life-threatening(Dengue Hemorrhagic fever and Dengue Shock Syndrome)
Antibody enhanced infection
Currently, there are no vaccines or specific treatment for dengue fever available. Treatment is limited to replenishing fluids and electrolytes. Therefore, early diagnosis that can distinguish between primary and secondary infections is critical to disease management allowing faster treatment and limit mortality and morbidity rates.
The Complete Solution For Dengue Diagnostics
Partnered with a leading discoverer, developer, and manufacturer of in-vitro diagnostic medical kits for tropical diseases, we are proud to offer a complete suite of products for the management of Dengue Fever:
OnSite Rapid Test Kits For All Markets
OnSite Rapid Tests are lateral flow immunochromatographic assays designed for use in a range of settings from well-equipped hospitals to remote emergency stations to aid in the diagnosis of a broad range of diseases. The benefits of point of care rapid tests include a rapid time to result, a simple procedure that can be performed without complicated equipment and a minimal need for training.
OnSite Dengue Rapid Test Procedure – Easy as 1,2, 3!
RecombLISA (ELISA) Kits To Ensure Rapid Test Quality
ELISA Tests are highly sensitive assays used to detect the presence of antigens or antibodies in a specimen to aid in the diagnosis of disease. The quality of antigens and antibodies against the target is the most important factor in producing ELISA tests with superior performance. The antigens and antibodies utilised in the ELISA kits are produced “in-house” which allows the complete control of and confidence in their tests.
Positiva Rapid Test Control Kit
To Confirm Rapid Test Results
Simple and effective quality control: Positivia Rapid Test Control Kits provide users with external controls to evaluate the integrity of the test, ensure users are performing the test correctly and enable compliance with regulatory requirements. Positivia External Controls are produced using recombinant protein engineering technology and are shipped lyophilized as conveniently portable yet comprehensive control systems.
REAGENTS For Research & Development
An array of high quality recombinant antigens and antibodies for use in research laboratories.
What Makes Our Dengue Product Range Unique?
Our products offer many advantages compared to other diagnostic methods:
Sensitivity (high-medium)
Specificity (high-medium)
Training requirement (low)
Resource requirement (low)
Faster time to results (15-25 minutes)
Use in unlimited settings
Other features:
The Dengue IgG and IgM Rapid Test and ELISA kit are IgG- and IgM-specific capture immunoassays that use recombinant dengue virus antigen developed with the latest technology as patented by the U.S. Center for Disease Control (U.S. CDC).
The use the affinity purified pan NS1 polyclonal antibody paired with multiple monoclonal antibodies that ensures NS1 detection for all four dengue serotypes as well as isolates.
The IgG and IgM antibody and NS1 antigen controls are developed with cutting-edge recombinant antibody and antigen technologies, produced by mammalian cells. Their supply is unlimited, and they can be transported to any country without being subjected to biohazardous regulations.
Recombinant E-protein, recombinant NS1 protein, and Pan NS1 polyclonal and monoclonal antibody are manufactured at our State-of-the-Art facility, located in the biotech hub of San Diego, California. These premium reagents are useful for the dengue research community, and are cited in many research publications.
Worldwide Health Concerns: Dengue and Zika Virus
On February 1, 2016, the World Health Organization (WHO) declared a Public Health Emergency in regards to Zika virus infection following the rapid increase of microencephaly cases in newborn babies whose mothers had an infectious history of the Zika virus during pregnancy.Dengue and Zika viruses are both members of the flavivirus family, transmitted by the same Aedes mosquitoes, and share many clinical symptoms. The cross-reactivity of antibodies between Zika and dengue is very common, making detection difficult and complicated. The first step in the Pan American Health Organization algorithm for the detection of Zika virus is to confirm the status of Dengue infection.
Additional Tropical Disease Tests
Other comprehensive diagnostic kits are avaliable to detect:
Chagas
Chikungunya
Filariasis
Leishmania
Leptospira
Malaria
Zika Virus (coming soon!)
Products are marked under the brands: OnSite, RecombLISA, Positivia and Aria. For more information, please contact sales@tlipng.com or visit here.
Other features:
The use the affinity purified pan NS1 polyclonal antibody paired with multiple monoclonal antibodies that ensures NS1 detection for all four dengue serotypes as well as isolates.
The IgG and IgM antibody and NS1 antigen controls are developed with cutting-edge recombinant antibody and antigen technologies, produced by mammalian cells. Their supply is unlimited, and they can be transported to any country without being subjected to biohazardous regulations.
Recombinant E-protein, recombinant NS1 protein, and Pan NS1 polyclonal and monoclonal antibody are manufactured at our State-of-the-Art facility, located in the biotech hub of San Diego, California. These premium reagents are useful for the dengue research community, and are cited in many research publications.
